-
Transcenta’s Osemitamab Combo Therapy Shows Promising Results in G/GEJ Cancer Treatment at ESMO 2024
•
Transcenta Holdings Ltd (HKG: 6628), a leading biopharmaceutical company, has announced updated positive results from the cohort-G data of its drug candidate osemitamab (TST001) in combination with nivolumab and CAPOX for the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) cancer at the 2024 European Society of Medical Oncology…
-
Transcenta Holdings Ltd Collaborates with Agilent Technologies on Companion Diagnostic for Osemitamab
•
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced a strategic agreement with Agilent Technologies to co-develop Claudin18.2 companion diagnostic reagents, marking a significant step in the global development of osemitamab combined with nivolumab plus chemotherapy for first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ)…
-
Transcenta Holdings Unveils Updated Osemitamab Data in Advanced Gastric Cancer at ESMO
•
China-based biotech Transcenta Holdings Ltd (HKG: 6628) has presented updated efficacy data from the expansion cohort of the TranStar102 trial at the ESMO Congress 2023 in Madrid, Spain. The trial assessed osemitamab (TST001), a high affinity humanized anti-CLDN18.2 monoclonal antibody (mAb) with enhanced antibody-dependent cellular cytotoxicity (ADCC), in combination with…
-
Transcenta Secures FDA Approval for Phase III Trial of Osemitamab
•
China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate the global Phase III pivotal TranStar study for its pipeline candidate, osemitamab (TST001). This clinical trial will evaluate the efficacy of osemitamab in combination with nivolumab and…
